ELDN

Insider Trades

Name	Value	Action	Price	Current Price
Bvf Partners L P/il10 Percent Owner $2.2k2.2M shares BuyOct 29, 2024 $0.001 --
Bvf Partners L P/il10 Percent Owner $2.1k2.1M shares BuyOct 29, 2024 $0.001 --
Bvf Partners L P/il10 Percent Owner $440440.5k shares BuyOct 29, 2024 $0.001 --

News

zacks.comIs Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?zacks.comJun 16

globenewswire.comEledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicineglobenewswire.comJun 8

globenewswire.comEledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessionsglobenewswire.comJun 4

zacks.comIs BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?zacks.comMay 29

Trade ELDN

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.

CEO: David-Alexandre C. Gros
IPO Date: Sep 17, 2014

Market Data

Open: $3.78
High: $3.96
Low: $3.75
Volume: 2.6M
Avg Volume: 1.4M
52W High: $4.60
52W Low: $1.35

Valuation

Market Cap: $235M
Enterprise Value: $229M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-62M
Revenue: $0
Net Income: $-46M
Cash: $23M
Debt: $641k

Events

EarningsAug 13

EPS est. -0.19